5 results about "Th2 cytokines" patented technology

Aspects of this application provide bispecific antibodies and methods of using them for treating conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis, by promoting barrier function and reducing inflammation. In some embodiments, the bispecific antibody includes at least one antigen-specific binding site that specifically binds to KLK5 and KLK7, and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or its receptor.

The invention provides a recombinant glycoprotein trimer vaccine for preventing SFTS and application thereof, the vaccine comprises a recombinant Gn or Gc glycoprotein trimer, and the recombinant Gn or Gc glycoprotein trimer is composed of a Gn or Gc protein fragment and a corresponding trimer motif; the amino acid sequences of the Gn and Gc protein fragments are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2, and the motif of the trimer is T4, DMPK, MTQ, MTI, hCorla, Langerin, T3XV, MATN1 or CAT. Results show that the neutralizing antibody level induced by the Gn or Gc trimer is superior to that of a corresponding monomer or dimer, and the Gn or Gc trimer has higher cross-neutralization activity. Meanwhile, monomers and trimers of Gn or Gc can induce high-level Th1 and Th2 cytokines and antibody-dependent cytotoxic effect (ADCC) response. According to the invention, a dominant antigen structure which can more effectively stimulate the generation of the neutralizing antibody in the SFTSV is defined, and a new target spot and a new strategy are provided for enhancing immunogenicity in the research and development of the SFTSV vaccine.

Aspects of the application provide bispecific antibodies and methods for using the same to promote barrier function and reduce inflammation and to treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. In some embodiments, the bispecific antibodies comprise at least one antigen-specific binding site that specifically binds to KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or a receptor thereof.

The present application relates to the field of biological medicine, and particularly relates to a composition for reducing stem cell transplantation rejection and application. The composition can reduce the proliferation and activation ability of T cells in combination with peptide I, peptide II and compound extract group. By combining with specific receptors on the surface of T cells, the calcium modulator phosphatase / NFAT pathway is blocked, the secretion of IFN-gamma and IL-2 and other cytokines is reduced, so that the proliferation and activation of T cells are inhibited. At the same time, the composition can induce the production of regulatory T cells and suppressor T cells, up-regulate the expression of TGF-beta and IDO, promote the differentiation of undifferentiated T cells into Treg cells, and enhance the inhibitory function of Treg cells; can also regulate Th1 / Th2 cytokine secretion, reduce Th1 type cytokine secretion, increase Th2 type cytokine secretion, and induce immune tolerance of the body.

The invention relates to the field of biological medicine, in particular to a composition for reducing stem cell transplantation rejection and application. The composition is combined with the peptide I, the peptide II and the compound extract group, so that the proliferation and activation capacities of T cells can be reduced. By combining with a specific receptor on the surface of a T cell, a calmodulin / NFAT pathway is blocked, and secretion of cell factors such as IFN-gamma and IL-2 is reduced, so that proliferation and activation of the T cell are inhibited. Meanwhile, the composition can induce generation of regulatory T cells and inhibitory T cells, promote differentiation of undifferentiated T cells to Treg cells by up-regulating expression of TGF-beta and IDO, and enhance the inhibition function of the Treg cells; th1 / Th2 cytokine secretion can also be regulated, so that Th1 type cytokine secretion is reduced, Th2 type cytokine secretion is increased, and body immune tolerance is induced.